Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINE: PF-07055480 (giroctocogene fitelparvovec) in Hemophilia A
NCT04370054Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Jun 2024
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of giroctocogene fitelparvovec in hemophilia A, sponsored by Pfizer. Primary endpoint: Total Annualized Bleeding Rate at 44.4 months. Started Aug 2020; status: active, not recruiting.
02
Drugs
giroctocogene fitelparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04370054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370054.